Free shipping on all orders over $ 500

Tozasertib

Cat. No. M1881
Tozasertib Structure
Synonym:

VX-680, MK-0457

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 70  USD70 In stock
10mg USD 40  USD40 In stock
25mg USD 72  USD72 In stock
50mg USD 120  USD120 In stock
100mg USD 200  USD200 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

Tozasertib (VX-680, MK-0457) is a small-molecule Aurora kinase inhibitor. The Aurora kinases are essential for the regulation of chromosome segregation and cytokinesis during mitosis. Tozasertib (VX-680) blocks cell-cycle progression and induces apoptosis in a diverse range of human tumor types. Tozasertib (VX-680) effectively inhibits proliferation of several different cell lines of clear cell renal carcinoma (IC50s < 10 μM) and blocks the growth of tumors in a rodent model of cancer (80 mg/kg), inhibiting H3 histone phosphorylation, to an increase of apoptotic cells, and to morphological changes such as vacuolization and swelling of the cells and nuclei. The combination of VX-680 and histone deacetylase inhibitor SAHA had a synergistic effect on the proliferation of HUH6 cells. Tozasertib (VX-680) might improve treatment results in HB with increased Aurora kinase activity by inhibiting cell proliferation and induction of apoptosis.

Product Citations
Customer Product Validations & Biological Datas
Source Journal of Hematology & Oncology (2017). Figure 7. VX680 (Abmole Bioscience)
Method CCK8 assay
Cell Lines U251, U87 and U118 cell lines
Concentrations
Incubation Time 48 and 72 h
Results We found that the U251-SIX3 cells showed less sensitivity to VX680 compared with the U251-CON cells (Fig. 7a). With increased expression of AURKA or AURKB and reduced expression of SIX3, the p53 mutant U251 cells were more sensitive to VX680 treatment, compared with the p53 wild-type U87 cells (Fig. 7b).
Protocol
Cell Experiment
Cell lines SW620, K562, HL-60, MIA PaCa-2 and HCT116 cells
Preparation method Analysis of cell proliferation and viability.
Tumor cells were seeded in 96-well plates and incubated with VX-680 for 96 h. To measure DNA synthesis, 0.5 mCi of [3H]thymidine was added to each well 3 h before the end of the experiment. Cells were then collected, and the incorporated radioactivity was counted on a Wallac microplate beta-counter. Cell viability was assessed using Promega CellTiter 96AQ to measure MTS (3-(4,5 dimethylthiazol-2-yl)-5-(3- carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) conversion.
Concentrations 1~10 μM
Incubation time 96 h
Animal Experiment
Animal models female athymic NCr-nu mice HL-60, MIA PaCa-2 and HCT116 cells tumour xenograft model
Formulation 50% PEG 300 in 50 mM phosphate buffer
Dosages q.4.d. at a dose of 12.5, 25, 50 and 75 mg/kg
Administration i.v.
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 464.59
Formula C23H28N8OS
CAS Number 639089-54-6
Purity 99.65%
Solubility DMSO 75 mg/mL
Storage 2-8°C, protect from light, dry, sealed
References

[1] Dewerth A, et al. Pediatr Surg Int. In vitro evaluation of the Aurora kinase inhibitor VX-680 for Hepatoblastoma.

[2] Fei F, et al. Mol Cancer Ther. Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias.

[3] Harrington EA, et al. Nat Med. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.

Related Aurora Kinase Products
LY3295668

LY3295668 (AK-01) is a potent, orally active and highly specific Aurora-A kinase inhibitor, with Ki values of 0.8 nM and 1038 nM for AurA and AurB, respectively.

SNS-314

SNS-314 is a potent and selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 9 nM, 31 nM, and 3 nM, respectively and less potent to Trk A/B, Flt4, Fms, Axl, c-Raf and DDR2.

Aurora Kinase Inhibitor III

Aurora Kinase Inhibitor III is a strong and selective Aurora A kinase inhibitor with an IC50 of 42 nM.

SNS-314 Mesylate

SNS-314 Mesylate is a potent and selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 9 nM, 31 nM, and 3 nM, respectively.

GSK1070916

GSK1070916 is a reversible and ATP-competitive inhibitor of Aurora B/C with IC50 of 3.5 nM/6.5 nM. It displays >100-fold selectivity against the closely related Aurora A-TPX2 complex.

  Catalog
Abmole Inhibitor Catalog




Keywords: Tozasertib, VX-680, MK-0457 supplier, Aurora Kinase, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.